- Home
- KAVL vs VRAX Comparison
KAVL vs VRAX Comparison
Compare KAVL & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAVL | VRAX |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 2.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | KAVL | VRAX |
|---|---|---|
| Price | $0.13 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 3.0M | ★ 15.3M |
| Earning Date | 09-16-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,127,037.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.35 |
| 52 Week High | $1.55 | $3.20 |
Technical Indicators
Market Signals| Indicator | KAVL | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 16.91 | 45.67 |
| Support Level | $0.47 | $0.43 |
| Resistance Level | $0.51 | $0.87 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.17 | 16.11 |
Price Performance
Historical ComparisonAbout KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).